Australian researchers explore proper dosing and tolerability in hypertensive subjects.
By Robby Gardner, Associate Editor
Garlic (Allium sativum L.) enjoys a heart-healthy reputation in the natural foods sector. Garlic powder, garlic oil, and aged garlic extract have all impressed in heart health trials and even in a recent meta-analysis. Now, researchers from the University of Adelaide in Australia are looking at aged garlic extract for hypertension (high blood pressure).
In the dose-response trial, researchers instructed 79 hypertensive adults to consume one, two, or four daily capsules of Kyolic aged garlic extract (240, 480, or 960 mg) or placebo for 12 weeks. Daily garlic doses contained 0.6, 1.2, or 2.4 mg of S-allylcysteine, an active constituent in garlic.
After weekly blood pressure measurements, researchers found no significant benefit of one daily capsule over placebo. Two daily capsules significantly lowered systolic blood pressure (mean 11.8 mm Hg) compared to placebo. Four daily capsules only reached borderline significant reductions at 8 weeks, a result that may have been influenced by poorer compliance and tolerability in this group. Overall, results of the trial led the researchers to conclude that at least 480 mg (the two-capsule dosage) of aged garlic extract can lower systolic blood pressure to a similar level of antihypertensive medications.
But the garlic trial was not without other challenges. One-third (35%) of subjects in the four-capsule garlic group reported minor side effects (including bloating, flatulence, and reflux), compared to 15% of subjects in the other garlic groups and just 5% of placebo users. Taking the extract at night instead of day did decrease reported side effects-but still.
“Although rare, gastrointestinal disturbances have been reported in other trials using therapeutic dosages of garlic by similar proportions of participants,” said the researchers.
The Royal Adelaide Hospital funded the aged garlic extract study, which is published in the European Journal of Clinical Nutrition.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.